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Summary
Abnormal folding of -synuclein (-syn) is thought
to lead to neurodegeneration and the characteristic
symptoms of Lewy body disease (LBD). Since previ-
ous studies suggest that immunization might be a po-
tential therapy for Alzheimer’s disease, we hypothe-
sized that immunization with human (h)-syn might
have therapeutic effects in LBD. For this purpose, h-
syn transgenic (tg) mice were vaccinated with h-syn.
In mice that produced high relative affinity antibodies,
there was decreased accumulation of aggregated h-
syn in neuronal cell bodies and synapses that was
associated with reduced neurodegeneration. Further-
more, antibodies produced by immunized mice recog-
nized abnormal h-syn associated with the neuronal
membrane and promoted the degradation of h-syn
aggregates, probably via lysosomal pathways. Sim-
ilar effects were observed with an exogenously ap-
plied FITC-tagged h-syn antibody. These results
suggest that vaccination is effective in reducing neu-
ronal accumulation of h-syn aggregates and that
further development of this approach might have a
potential role in the treatment of LBD.
Introduction
Lewy body disease (LBD) is a heterogeneous group of
disorders that includes Parkinson’s disease (PD) and
dementia with Lewy bodies (DLB) (Hansen and Ga-
lasko, 1992; Kosaka et al., 1984; McKeith, 2000), char-
acterized by degeneration of the dopaminergic system
(Shastry, 2001), motor alterations (Braak et al., 2002),
cognitive impairment (Salmon et al., 1996), and forma-
tion of Lewy bodies (LBs) in cortical and subcortical
regions (Trojanowski and Lee, 1998). The number of pa-
tients affected by these devastating conditions contin-
ues to climb as the population ages, creating a serious
public health problem. The cause for LBD is controver-
sial, and multiple factors probably play a role, including
various neurotoxins and genetic susceptibility factors
(Betarbet et al., 2000; Coleman et al., 1996; D’Amato et
al., 1986; Forno et al., 1996; Jenner, 1998; Veldman et
al., 1998).*Correspondence: emasliah@ucsd.eduIn recent years, new hope for understanding the
pathogenesis of this disease has emerged. Specifically,
several studies have shown that the synaptic protein
α-synuclein (α-syn) (Iwai et al., 1994) plays a central
role in LBD pathogenesis since (1) this molecule accu-
mulates in LBs (Spillantini et al., 1997; Takeda et al.,
1998b; Wakabayashi et al., 1997), (2) mutations and
multiplication in the α-syn gene are associated with
rare familial forms of parkinsonism (Kruger et al., 1998;
Polymeropoulos et al., 1997; Singleton et al., 2003), and
(3) its expression in transgenic (tg) mice (Lee et al.,
2002; Lee et al., 2004b; Masliah et al., 2000) and Dro-
sophila (Feany and Bender, 2000) mimics several as-
pects of PD. Thus, the fact that accumulation of α-syn
in the brain is associated with similar morphological
and neurological alterations in species as diverse as
humans, mice, and flies suggests that this molecule
contributes to the development of LBD.
The mechanisms by which accumulation of α-syn
leads to neurodegeneration and the characteristic
symptoms of LBD are unclear. However, recent studies
suggest that abnormal accumulation of α-syn oligo-
mers in the synaptic terminals and axons plays an im-
portant role (Hashimoto and Masliah, 1999; Iwatsubo et
al., 1996; Lansbury, 1999; Trojanowski et al., 1998).
Although experimental therapies utilizing neurotro-
phic factors (Kirik et al., 2004) and grafting of dopa-
minergic cells (Kim, 2004; Yoshizaki et al., 2004) have
yielded promising results, alternative approaches di-
rected at reducing the neuronal accumulation of α-syn
are necessary. Viable strategies might include the use
of viral vectors expressing antiaggregation molecules
(Burton et al., 2003; Hashimoto et al., 2004) or factors
such as immunotherapy, which promote the degrada-
tion or clearance of α-syn. For example, recent studies
in a tg mouse model of Alzheimer’s disease (AD) have
shown that antibodies against β-amyloid 1-42 (Aβ) pro-
mote the removal of amyloid from the brain, resulting
in improved cognitive performance (Janus et al., 2000;
Morgan et al., 2000; Schenk et al., 1999). Moreover, a
vaccination approach has been shown to be effective
experimentally in tg mice at reducing the accumulation
of prion protein (Sigurdsson et al., 2002) and huntingtin
(Luthi-Carter, 2003; Miller et al., 2003), molecules that,
like α-syn, accumulate intracellularly. In this context,
we postulate that immunization of human (h)α-syn tg
mice (a mouse model of LBD) with purified recombinant
hα-syn might activate an immune response that will re-
duce hα-syn accumulation and, more importantly, neu-
rotoxicity. This approach may be a suitable target for
the development of an alternative immune therapy for
PD and other disorders with LBs, parkinsonism, and
dementia.
Results
Characterization of Antibody Titers, Relative Affinity,
and Epitope Mapping
Three-month-old tg mice for group I and six-month-old
tg mice for group II were immunized for 8 months with
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858recombinant hα-syn or Complete Freund’s adjuvant s
t(CFA) alone. Antibody titers in animals belonging to
group I ranged from 200 to 20,000 (Table 1), and in mice w
sfrom group II, titers ranged from 200 to 13,000 (Table
1). Levels of antibody relative affinity by immunoblot- n
iting were higher in mice from group II compared to im-
munized mice from group I (Table 1). By immunocyto- a
chemistry (ICC), sera from mice vaccinated with hα-syn
showed either labeling of neurons (Figure 1A), intraneu- I
aronal inclusions (Figure 1B), or presynaptic terminals
(Figure 1C) in hα-syn tg mice, but only displayed mild T
bbackground staining in nontg mice (Figure 1D). Sera
from mice treated with CFA alone showed nonspecific w
(background staining in both hα-syn tg (Figure 1E) and
nontg (Figure 1F) mice. By Western blot (WB) analysis, a
lsera from mice vaccinated with hα-syn recognized hα-Table 1. Summary of hα-Syn Antibody Titers and Relative Affinity, Corrected for Titer
Antibody Relative Antibody Affinity Antibody Affinity Antibody Titers Antibody Titers Antibody Titers
Group Affinity by Miniblot to Synapses to Inclusions (First Bleed) (Second Bleed) (Third Bleed)
Group I/α-syn 109,147 ± 2700 1.9 ± 0.73 1.2 ± 0.4 2332 ± 500 2772 ± 1176 3644 ± 2365
Group I/CFA 113 ± 113 0.4 ± 0.1 0 19 ± 6.7 30 ± 12 7 ± 4
Group II/α-syn 235,747 ± 74,000 4.1 ± 0.9 2.8 ± 1.0 3813 ± 1200 2926 ± 976 1468 ± 641
Group II/CFA 400 ± 358 0.3 ± 0.2 0.1 ± 0.1 23 ± 9 21 ± 14 0.6 ± 0.6inear regression analysis shows that antibody relative
Figure 1. Immunocytochemical and Immunoblot Analysis with the Sera from Vaccinated Mice in the Brains of nontg and hα-Syn tg Mice
For panels (A)–(F), serial vibratome sections from nonimmunized hα-syn tg (Line D, 6-month-old) and nontg mice were immunostained with
sera (normalized to 1:1000) from CFA and hα-syn-vaccinated (vacc) animals. All panels are from the temporal cortex. (A–C) Sections from hα-
syn tg mice immunolabeled with the sera from immunized mice displayed neuronal staining (A), inclusion body staining (B), and granular
neuropil immunolabeling suggestive of presynaptic terminals (C). (D) Section from a nontg mouse immunostained with the sera from immu-
nized mice shows only mild background staining. (E and F) Sections from hα-syn tg (E) and nontg (F) mice immunolabeled with sera from
CFA-treated mice showed only nonspecific background staining of the neuropil. Scale bar, 40 m. For panels (G) and (H), homogenates from
the brains of hα-syn tg mice treated with CFA or immunized with hα-syn were resolved by SDS-PAGE, and blots were probed with the sera
from treated mice. (G) Immunoblot analysis with the sera from vaccinated mice shows a prominent band at approximately 19 kDa correspond-
ing to recombinant hα-syn (lane 1, α-s), hα-syn in the brains of tg animals treated with CFA (lanes 3 through 5) or vaccinated with hα-syn
(lanes 6 through 8). The sera did not recognize recombinant β-syn (lane 2, β-s). (H) Immunoblot analysis with the sera from CFA-treated
animals shows no IR to recombinant hα-syn (lane 1, α-s), recombinant β-syn (lane 2, β-s) or in the brains of tg animals treated with CFA (lanes
3 through 5) or vaccinated with hα-syn (lanes 6 through 8).yn in tg mice (Figure 1G). In contrast, no immunoreac-
ivity (IR) was observed with sera from mice treated
ith CFA alone (Figure 1H). Epitope mapping studies
howed that in the vaccinated mice, antibodies recog-
ized epitopes within the C terminus region of hα-syn,
ncluding amino acids (aa) 85–99, 109–123, 112–126,
nd 126–138.
mmunization Reduces h-Syn Accumulation
nd Preserves Synaptic Density in tg Mice
o determine the effects of immunotherapy and anti-
ody relative affinity on hα-syn accumulation, sections
ere analyzed by ICC with antibodies against hα-syn
Figure 2). Since antibody relative affinity (Figure 3A)
nd titers (Table 1) show a wide range of variability and
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859Figure 2. Patterns of hα-Syn IR and Glial Re-
sponse in the Brains of Immunized hα-Syn
tg Mice
Panels are from the temporal cortex of CFA
or hα-syn-vaccinated mice reacted with anti-
bodies against hα-syn, Iba1, or GFAP, devel-
oped with DAB, and analyzed by bright field
microscopy. Panels (A)–(C) are representa-
tive images from the brains of group I mice
(11-month-old), and panels (D)–(L) are from
the brains of group II mice (14-month-old).
Mice from both groups were divided into
subsets of animals that produced antibodies
with low (<100,000 units) or high (>100,000
units) relative affinities to hα-syn. (A and D)
CFA-treated mice showed abundant hα-syn
IR in intraneuronal inclusions as well as the
neuropil. (B, E, C, and F) Immunized mice
that produce low relative affinity (B and E)
antibodies display a modest decrease in hα-
syn-immunoreactive inclusions and neuropil
labeling, and those that produce high rela-
tive affinity antibodies (C and F) demonstrate
a more significant decrease in hα-syn-immu-
noreactive inclusions and neuropil labeling.
(G–L) Compared to CFA-treated mice (G and
J), animals vaccinated with hα-syn show
only a mild increase in microglial IR (Iba-1,
[H and I]) and mild astroglial activation
(GFAP, [K and L]). Scale bar, 50 m.affinity was one of the strongest predictors for the ef-
fects on reducing the neuropathology on the vacci-
nated hα-syn tg mice (Table 2), animals were divided
into subgroups consisting of those that show low
(<100,000 units; Figures 2B, 2E, 2H, and 2K) and high
(>100,000 units; Figures 2C, 2F, 2I, 2L, and 3A) relative
affinity to hα-syn (expressed as units of intensity vol-
ume). In tg mice treated with CFA alone, abundant hα-
syn IR was observed in the neuropil as well as in intra-
neuronal inclusions (Figures 2A and 2D). In contrast,
immunized mice from both groups showed a reduction
in the number of inclusions in the temporal cortex (Fig-
ure 3B). Compared to mice producing low relative affin-
ity antibodies (Figures 2B and 2E), this effect was more
pronounced in mice producing antibodies with high rel-
ative affinity to hα-syn (Figures 2C and 2F). Moreover,
immunization resulted in a decrease in hα-syn IR in the
neuropil of tg mice producing antibodies with high rela-
tive affinity to hα-syn (Figures 2C and 2F), with a greater
effect in mice from group II (Figure 2F) than group I
(Figures 2C and 3D), compared to CFA-treated tg mice
(Figures 2A and 2D). To investigate whether the effects
of the immunization were accompanied by a neuro-
inflammatory response, immunocytochemical analysis
with antibodies against the microglial marker (Iba-1)
and the astroglial marker (glial fibrillary acidic protein
[GFAP]) were performed. These studies showed that in
both CFA-treated (Figures 2G and 2J) and hα-syn-vac-
cinated (Figures 2H, 2I, 2K, and 2L) animals, there was
a mild increase in Iba-1 and GFAP IR; however, no overt
differences were detected between the groups.
To further investigate the effects of the vaccination
on the synapses, higher-resolution analysis with the la-
ser scanning confocal microscope (LSCM) was per-
formed. These studies confirmed that compared to CFAcontrols (Figures 3D, 4A, and 4C) the reduction in the
neuropil immunostaining was associated with decreased
accumulation of hα-syn in presynaptic terminals (Fig-
ures 3D, 4B, and 4D). To ascertain the effects of the
immunotherapy on neuropil integrity, sections were im-
munostained with an antibody against synaptophysin
(Figures 4E–4H). Compared to nontg mice, hα-syn tg
mice treated with CFA alone (Figures 4E and 4G) showed
an average of 20% decrease in the number of synapto-
physin-immunolabeled terminals (Figure 3C). In con-
trast, immunized mice from both groups I and II showed
levels of synaptophysin IR comparable to nontg con-
trols (Figures 3C, 4F, and 4H). This effect was more
prominent in mice that produced antibodies with high
relative affinity to hα-syn (Figure 3C).
To rule out immunization masking effects, control ex-
periments were performed by comparing the levels of
murine (m)α-syn. Similar to hα-syn, mα-syn IR was
abundant in the neuropil in association with nerve ter-
minals, but was absent from the neuronal cell bodies
and in the inclusions (Figures 4I–4L). Both in CFA (Fig-
ures 4I and 4K) and hα-syn immunized mice (Figures 4J
and 4L), patterns and levels of mα-syn were compara-
ble. Additional analysis of the immunization specificity
was performed by comparing levels of β-syn IR, a close
α-syn homolog (Iwai et al., 1994). Abundant β-syn IR
was observed in the neuropil in association with the
presynaptic terminals, and mild immunolabeling was
detected in the neuronal cell bodies, but not in the in-
clusions (Figures 4M–4P). Compared to tg mice treated
with CFA alone (Figures 4M and 4O), no differences in
the patterns and levels of β-syn were found in mice
immunized with hα-syn (Figures 4N and 4P). These
studies suggest that vaccination specifically affects
hα-syn but not other related synaptic molecules.
Neuron
860Figure 3. Image Analysis of the Levels of hα-
Syn IR and Other Markers of Neurodegener-
ation
(A) Relative affinity by mini-blot of hα-syn an-
tibodies produced by mice treated with CFA
alone or immunized with hα-syn was as-
sessed. (B) Scatterplot of number of hα-syn-
positive inclusions in the temporal cortex of
mice treated with CFA alone or immunized
with hα-syn. Vaccination resulted in a signifi-
cant decrease in the number of inclusions in
both groups compared to controls, an effect
more pronounced in group II mice (14-
month-old) as opposed to group I (11-
month-old). (C) Percent area of the neuropil
occupied by synaptophysin-immunoreactive
terminals in the temporal cortex. Compared
to nontg controls, in tg mice treated with
CFA alone, the number of synaptophysin-
immunolabeled terminals decreased by an
average of 20%. In contrast, tg mice from
both groups showed levels of synaptophysin
IR comparable to nontg controls. (D) Percent
area of the neuropil occupied by hα-syn-
immunoreactive terminals in the temporal
cortex. In tg mice from both groups vac-
cinated with hα-syn, there was a decrease
in the accumulation of hα-syn in synapto-
physin-immunoreactive terminals. (E) Levels
of cathepsin D IR (measured as pixel inten-
sity) in CFA-treated and hα-syn-vaccinated
tg mice. In vaccinated tg mice, there were
significantly higher levels of cathepsin D IR
in both groups compared to CFA controls.
* = significant difference compared to CFA-
treated hα-syn tg mice (p < 0.05, unpaired,
two-tailed Student’s t test).To better characterize the effects of vaccination on l
shα-syn aggregation in the synapses, double immuno-
cytochemical analysis with antibodies against hα-syn l
iand the presynaptic terminal marker synaptophysin
and WB analysis with synaptosomal preparations were i
operformed. Under physiological conditions, hα-syn is
localized primarily to the presynaptic boutons (Iwai et
al., 1994), and in LBD and the tg mice, increased accu- I
Amulation of hα-syn in the synapses is associated with
functional deficits and synapse loss (Hashimoto et al., A
S2001). Confocal imaging showed that in comparison to
CFA-treated hα-syn tg mice (Figure 3D), vaccinated w
mmice displayed a decrease in the proportion of synap-
tophysin-immunoreactive nerve terminals in the neo- t
hcortex that show hα-syn immunolabeling (Figure 3D).
Immunoblot analysis with synaptosomal preparations a
5(Figure 5A, upper panel) showed that immunization de-
creased the accumulation of hα-syn higher molecular h
wweight bands (Figure 5A, upper panel, and Figure 5B),
but no effects were observed on mα-syn (data not h
shown). Furthermore, compared to CFA-treated tg mice,evels of synaptophysin IR were higher in the synapto-
omal preparations from immunized mice (Figure 5A,
ower panel, and Figure 5B). These results suggest that
mmunotherapy might ameliorate the neuronal damage
n the brains of tg mice by reducing the accumulation
f potentially toxic hα-syn in the synapses.
mmunization Effects Are Dependent on the Relative
ffinity of Antibodies to Recognize Membrane-
ssociated Aggregated h-Syn
ince abnormal accumulation of hα-syn is associated
ith translocation of hα-syn from the cytosol to the
embrane, it is possible that this might explain the an-
ibodies’ ability to recognize abnormally accumulated
α-syn in the immunized tg mice. WB analysis showed
bundant monomeric hα-syn in both the cytosol (Figure
C) and membrane (Figure 5D). However, oligomeric
α-syn was more abundant in the membrane fractions
here, compared to CFA controls, immunization with
α-syn resulted in decreased accumulation of hα-synoligomers (Figure 5D).
α-Synuclein Immunization in PD tg Mice
861activation, cathepsin D IR was analyzed. Compared toof neuronal hα-syn accumulation.
Table 2. Summary of Correlations between Antibody Relative Affinity, Neuropathology, and Titers
Antibody Relative Antibody Affinity Antibody Affinity Antibody Affinity Antibody Titers
Neuropathological Markers Affinity by Miniblot to Synapses to Inclusions to Neurons (First Bleed)
Number of α-syn (+) inclusions −0.11 0.04 0.12 −0.21 0.1
% area of neuropil α-syn (+) −0.46 (p = 0.003) −0.41 (p = 0.009) −0.43 (p = 0.005) 0.06 −0.47 (p = 0.007)
synapses
% area of neuropil 0.06 0.35 (p = 0.04) 0.01 0.04 0.12
synaptophysin (+) synapses
Antibody relative affinity — 0.74 (p = 0.0001) 0.70 (p = 0.0001) −0.16 0.85 (p = 0.0001)
by miniblotFigure 4. Immunocytochemical Analysis of
hα-Syn, Synaptophysin, mα-Syn, and β-Syn
IR in the Brains of hα-Syn tg Mice from
Groups I and II
All panels are from the temporal cortex of
CFA-treated or vaccinated mice. Group I, 11-
month-old; group II, 14-month-old. (A–D)
Sections were reacted with an antibody
against hα-syn, labeled with Tyramide Red
and imaged with the LSCM. Compared to tg
mice treated with CFA alone (A and C), im-
munized mice (B and D) showed a reduction
in the number of inclusions in the temporal
cortex as well as a decrease in hα-syn IR
(presynaptic terminals) in the neuropil. (E–H)
Sections were immunostained with an anti-
body against synaptophysin and FITC-
labeled for imaging with the LSCM. In tg
mice treated with CFA alone (E and G), levels
of synaptophysin IR were reduced, whereas
immunized mice showed levels of synapto-
physin IR comparable to nontg controls.
(I–P) Sections were reacted with an antibody
against mα-syn and labeled with Tyramide
Red (I–L) or with an antibody against and
β-syn and FITC-labeled (M–P), and imaged
with the LSCM. (I–L) Levels of endogenous
mα-syn remain unchanged in tg mice treated
with CFA alone (I and K) and immunized mice
(J and L). All display mα-syn IR in the neu-
ropil, but there is no labeling of the intraneu-
ronal inclusions as is found with antibodies
against hα-syn. (M–P) Both hα-syn tg mice treated with CFA alone (M and O) and tg mice vaccinated with hα-syn (N and P) display abundant
β-syn IR in the neuropil and mild immunolabeling in the neuronal cell bodies, but there is no labeling of the intraneuronal inclusions as is
found with antibodies against hα-syn. Scale bar, 10 m.To better understand which factors might predict the
effectiveness of the immunotherapy, linear regression
analysis was performed between the neuropathological
markers of hα-syn accumulation and the antibody titers
and relative affinity (Table 2). A significant correlation
was observed between relative antibody affinity by im-
munoblot and levels of hα-syn IR in the synapses, but
not with the numbers of neuronal inclusions. Similarly,
relative antibody affinity to recognize synapses by ICC
was inversely correlated with levels of hα-syn in the
synapses and directly correlated with the percent area
occupied by synaptophysin-labeled nerve terminals,
but not with the numbers of neuronal inclusions. Anti-
body titers correlated with the percent area of the neu-
ropil labeled with the anti-hα-syn antibody, but nega-
tively correlated with neuronal inclusions (Table 2).
These results suggest that the relative immunoblot re-
activity of the anti-hα-syn antibodies and to some ex-
tent the antibodies’ titers correlate with the reductionAntibody titers (first bleed) 0.85 (p = 0.0001) 0.62 (p = 0.0001)Anti-h-Syn Antibodies Are Internalized and Trigger
Clearance of h-Syn Aggregates
via Lysosomal Activation
To determine if anti-hα-syn antibodies generated by the
immunized mice recognize hα-syn aggregates in the tg
mice, immunocytochemical analysis was performed
with horse anti-mouse IgG antibodies. Double immuno-
staining experiments showed that compared to CFA-
treated tg mice (Figures 6A–6C), in hα-syn vaccinated
mice, the anti-mouse IgG and the hα-syn IR were colo-
calized in the periphery of the cell bodies (Figures 6D–
6F), the neuritic processes and synapses (Figures 6G–
6I). In hα-syn containing neurons, the two markers were
detected in granular subcellular structures averaging
0.4–0.8 m in diameter (Figures 6G–6L). Furthermore,
these granular structures displayed cathepsin D IR,
suggesting that the internalized anti-hα-syn antibodies
reacted with hα-syn within lysosomes (Figures 6M–6O).
To corroborate that vaccination resulted in lysosomal−0.18 0.81 (p = 0.0001) —
Neuron
862Figure 5. WB Analysis of the Levels of
hα-Syn IR in Synaptosomal, Membrane, and
Cytosolic Preparations from Vaccinated An-
imals
(A and B) Compared to brains of tg mice
treated with CFA alone (lanes 1 through
6), in hα-syn-vaccinated tg mice (lanes 7
through 12), levels of hα-syn oligomers were
decreased (upper panel), while levels of syn-
aptophysin IR increased in the immunized
animals (lower panel). (C and D) Compared
to the cytosolic fraction of the brains of tg
mice (C), a majority of hα-syn high molecular
weight oligomers are present in the mem-
brane fraction (D), where compared to mice
treated with CFA alone (lanes 1 through 6),
there is a decrease in hα-syn oligomers in
the fractions from vaccinated animals (lanes
7 through 12). * = significant difference com-
pared to hα-syn tg mice treated with CFA
alone (p < 0.05, unpaired, two-tailed Stu-
dent’s t test). Animals were 14 months old.CFA controls (Figures 7A–7C), in vaccinated mice there (
fwas increased cathepsin D IR (Figures 3E and 7D–7F).
Similar increases in levels of cathepsin D IR were de- m
ctected in the hα-syn-vaccinated mice from both groups
when compared to the CFA-treated group (Figure 3E). 2
iIn vaccinated tg mice, the cathepsin D-immunolabeled
lysosomes were colocalized with discrete hα-syn- 2
simmunoreactive granular aggregates (Figure 7F), but no
colocalization was observed in CFA-treated tg mice W
c(Figure 7C).
To determine if exogenously applied antibodies rec- p
tognize hα-syn aggregates in tg mice and activate lyso-
somal pathways, purified monoclonal anti-hα-syn anti- W
tbodies were tagged with fluorescein isothiocyanate
(FITC) and injected into tg and nontg animals. The p
pFITC-tagged anti-hα-syn recognized hα-syn aggre-
gates in the neuronal cell bodies and synapses of tg t
nanimals (Figure 7G–I), but not the endogenous mα-syn
in the nontg controls (Figures 7J–7L). Furthermore, in o
ptg mice treated with the FITC-tagged antibody, there
was an increase in neuronal cathepsin D IR and colo- a
acalization with hα-syn (Figures 7M–7O) compared to
nontg controls (Figures 7P–7R). No specific labeling of f
thα-syn or increase in cathepsin D IR was detected in
control experiments where tg and nontg mice were m
htreated with a nonimmune FITC-tagged IgG (data not
shown). These studies suggest that circulating antibod- a
ies might recognize abnormally aggregated hα-syn as- a
sociated with the neuronal membrane, which in turn b
might lead to clearance via lysosomal activation. a
(
pDiscussion
t
pThe present study showed that hα-syn antibodies gen-
Derated in vaccinated mice reduced the abnormal accu-
omulation of this protein in the neuronal cell bodies and
ssynapses and ameliorated the loss of synaptophysin-
simmunoreactive nerve terminals in hα-syn tg mice. This
iis consistent with recent in vitro studies showing that
intracellular antibodies can inhibit α-syn aggregation cEmadi et al., 2004; Zhou et al., 2004). Moreover, our
indings are consistent with studies showing that im-
unotherapy might reduce the accumulation of extra-
ellularly deposited proteins such as Aβ (Games et al.,
000; Lemere et al., 2003; Morgan et al., 2000) and of
ntracellular proteins such as huntingtin (Luthi-Carter,
003), as well as membrane-associated molecules
uch as prion proteins (Bainbridge and Walker, 2003;
hite et al., 2003; White and Hawke, 2003). More re-
ently, a study showed that immunotherapy with co-
olymer-1-immune cells might reduce neurodegenera-
ion in the MPTP model of PD (Benner et al., 2004).
hile this immunotherapy approach focused on pro-
ecting via a general anti-inflammatory mechanism, the
resent study sought to elicit a specific response to
romote degradation of toxic hα-syn. The mechanisms
hrough which the antibodies generated in the vacci-
ated mice might recognize and promote the clearance
f intracellular hα-syn aggregates and other neuronal
roteins are less clear. One possibility is that circulating
ntibodies in the CNS might recognize and cross-link
bnormally conformed proteins in the neuronal cell sur-
ace (Figure 8). For this, at least a limited amount of
he target antigen must be present in the neuronal cell
embrane (Luthi-Carter, 2003). A similar mechanism
as been described in the antibody-mediated clear-
nce of viruses from cells (Garzon et al., 1999; Ubol et
l., 1995). Interestingly, in the case of α-syn, under
asal conditions the monomeric forms of this molecule
re almost exclusively present in the cytosolic fraction
Eliezer et al., 2001; Iwai, 2000). In contrast, under
athological circumstances leading to α-syn aggrega-
ion, oligomers and protofibrils can be found in the
lasma membrane (Eliezer et al., 2001; Lansbury, 1999;
ixon et al., 2005), where they could potentially be rec-
gnized by circulating antibodies. Supporting this pos-
ibility, immunoblot and immunocytochemical analysis
howed that vaccination reduced hα-syn accumulation
n the membrane and that mouse IgG and hα-syn were
olocalized in the periphery of the neurons, suggesting
α-Synuclein Immunization in PD tg Mice
863Figure 6. Double Immunocytochemical Analy-
sis of the Patterns of hα-Syn and anti-IgG or
Cathepsin D IR in Vaccinated Animals
All images are from the temporal cortex.
Sections from CFA-treated and hα-syn vac-
cinated animals from group II were double
labeled with antibodies against hα-syn (pan-
els to the left, red) and FITC-tagged anti-
mouse IgG or cathepsin D (central panels,
green) and imaged with the LSCM. The
images to the right represent the merged
panels (yellow indicates colocalization of the
two markers), demonstrating that neuronal
cell bodies labeled by the anti-mouse IgG
and the intraneuronal granular structures la-
beled by cathepsin D displayed hα-syn IR
(arrows). (A–C) Tg mice treated with CFA
show characteristic inclusions that react
strongly with hα-syn antibodies and show
background levels of reactivity with anti-
mouse IgG. (D–F) Tg mice vaccinated (vacc)
with hα-syn show a close colocalization be-
tween hα-syn and anti-mouse IgG in the
periphery of the neuronal cell bodies. (G–L)
Additionally, the anti-mouse IgG immuno-
staining is colocalized with hα-syn in small
granular structures within the cell bodies (ar-
rows). (M–O) These small granular structures
also displayed lysosomal cathepsin D IR that
colocalized with hα-syn immunolabeling.
Scale bar, 10 m (A–I), 5 m (J–L). Animals
were 14 months old.that such interactions might take place in the neuronal
surface.
Since circulating antibodies might be able to recog-
nize membrane bound α-syn, there are several possi-
bilities as to how they might promote the clearance of
intracellular aggregates. Antibodies in close opposition
with the neuronal surface might enter the neurons alone
via surface receptors or in association with membrane
bound α-syn and promote lysosomal degradation (Fig-
ure 8). This process may be mediated by receptor-
dependent or receptor-independent endocytosis of the
antibody or antibody-antigen complex, followed by fu-
sion with lysosomes and incorporation of α-syn aggre-
gates (Figure 8). Supporting this possibility, anti-mouse
IgG, an exogenously applied FITC-tagged anti-hα-syn
antibody, and cathepsin D colocalized with hα-syn ag-
gregates. Consistent with the possibility that internal-
ization of the antibody complex might play a role in
clearance of α-syn aggregates, previous studies have
shown that neurons can uptake immunoglobulins (Fab-
ian and Petroff, 1987) and internalize some through theThy 1.1 receptor in the neuronal and synaptic plasma
membrane (Fabian, 1990). Other receptors that might
be involved in this process and mediate the endocyto-
sis of antibodies or antibody-antigen complexes in-
clude lipoprotein receptor-related protein (LRP) (Herz et
al., 1990; Kounnas et al., 1995). This receptor is highly
abundant in neurons (Schneider and Nimpf, 2003; Hus-
sain, 2001), and macromolecules endocytosed via LRP
target the lysosomal pathway (Gonias et al., 2004), sug-
gesting that clearance of intracellular hα-syn aggre-
gates might involve lysosomal degradation. In support
of this mechanism, the present study showed that in
the neurons of vaccinated mice, granular hα-syn-immu-
noreactive structures were also labeled with antibodies
against the lysosomal marker cathepsin D. Similarly,
previous studies have shown that immunoglobulins in-
ternalized by neurons form granular cytoplasmic struc-
tures that display lysosomal-like activity (Meeker et al.,
1987). Moreover, recent studies have shown that lyso-
somally dependent autophagy might facilitate the
clearance of α-syn oligomers (but not fibrils) and there-
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864Figure 7. Antibody Recognition of hα-Syn
and Lysosomal Activation in Vaccinated hα-
Syn tg Animals
All panels are LSCM images from the temporal
cortex. Panels (A)–(F) are from CFA-treated or
immunized hα-syn tg mice from group II (14-
month-old), and panels (G)–(R) are from non-
immunized nontg and hα-syn tg animals
(5-month-old) that received intracerebral injec-
tions of an FITC-tagged hα-syn antibody. (A–
C) Images from sections of a hα-syn tg mouse
treated with CFA alone double immunolabeled
with antibodies against hα-syn (red) and the
lysosomal marker cathepsin D (green). (D–F)
Images from sections of a vaccinated hα-
syn tg mouse double immunostained with
antibodies against hα-syn (red) and cathepsin
D (green). Yellow indicates colocalization be-
tween granular hα-syn-immunoreactive struc-
tures and cathepsin D (arrows). Note the
higher levels of cathepsin D IR in these
images. (G–I) Images from sections of a hα-
syn tg mouse that received intracerebral injec-
tions of an FITC-tagged antibody against hα-
syn (green) coimmunolabeled with a different
antibody against hα-syn (red). Yellow indicates
colocalization between injected and immuno-
labeled anti-hα-syn antibodies. (J–L) Images
from sections of a nontg mouse that received
intracerebral injections of an FITC-tagged anti-
body against hα-syn (green) coimmunolabeled
with a different antibody against hα-syn (red).
(M–O) Images from sections of a hα-syn tg
mouse that received intracerebral injections
of an FITC-tagged antibody against hα-syn
(green) coimmunolabeled with an antibody
against cathepsin D (red). Yellow indicates
colocalization between hα-syn and cathepsin
D (arrows). (P–R) Images from sections of a
nontg mouse that received intracerebral injec-
tions of an FITC-tagged antibody against hα-
syn (green) coimmunolabeled with an antibody
against cathepsin D (red). Scale bar, 15 m.fore may play a protective role (Cuervo, 2004; Cuervo m
iet al., 2004; Lee et al., 2004a). These studies suggest
that in the immunized mice, internalized antibodies s
cmight promote degradation of hα-syn aggregates via
activation of lysosomal pathways. Alternatively, active p
avaccination might also promote the clearance of α-syn
aggregates via an immune-mediated cellular response. a
wThis is unlikely, because in the present study, no appar-
ent infiltration by lymphocytes was noted and only mild p
Amicroglial activation was detected. However, it is im-
portant to consider this possibility because active im- n
amunization in other neurodegenerative disorders has
been associated in some cases with vasculitis and au- R
otoimmune response (Ferrer et al., 2004), and caution
should be exercised when considering the use of active t
Mimmunization as a potential therapy in patients with PD.
For this reason we are currently investigating the ef- 1
afects of passive immunization with antibodies against
various regions of α-syn. t
aAntibodies against α-syn not only decreased accu-
mulation in neuronal cell bodies, but also in neuropil, (
asuggesting that the immunotherapy also reduced the
accumulation of hα-syn aggregates in the synapses. a
pThis effect was associated with amelioration of the neu-rodegenerative pathology. It is unclear whether thisight be accompanied by the improvement of behav-
oral deficits; experiments are currently underway to as-
ess this possibility. The ability of the antibodies to re-
ognize neuronal cell bodies and synapses was a good
redictor of their ability to reduce hα-syn aggregation
nd neurodegeneration at least as determined by syn-
ptic integrity. This is consistent with studies in AD,
here antibodies with high affinity for plaques dis-
layed a better response (Hock et al., 2002). While for
β, the most effective antibodies recognize the N termi-
us (Bard et al., 2003), for hα-syn, high relative affinity
ntibodies recognized epitopes within the C terminus.
ecent studies have shown that C-terminal fragments
f α-syn assemble into protofibrils and associate with
he membrane (McLean et al., 2000; Kim et al., 2002;
cLean et al., 2000). Deletion of key amino acids 125–
40 within the C-terminal domain greatly alters α-syn
ggregation (Kim et al., 2002), and in the brains of pa-
ients with LBD as well as in tg animal models, there is
bundant accumulation of C-terminal α-syn fragments
Iwatsubo et al., 1996; Takeda et al., 2000; Takeda et
l., 1998a). These studies suggest that the antibodies’
bility to recognize the C-terminal region might be im-
ortant for the therapeutic effects.
Considerable effort has recently been directed to-
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865ward the development of immunization therapies for
neurodegenerative disorders, including the use of ac-
tive and passive immunization strategies (Frenkel and
Solomon, 2001; Morgan et al., 2000; Schenk et al.,
1999), DNA vaccination (Luthi-Carter, 2003), and, more
recently, adoptive transfer of immune cells to protect
nigrostriatal neurons (Benner et al., 2004). Adding to
this growing body of evidence supporting a role of im-
munization in the management of neurodegenerative
disorders, the present study suggests that vaccination
is effective in reducing the neuronal accumulation of
toxic hα-syn aggregates and that further development
of this approach might have a potential place in the
treatment of LBD.
Experimental Procedures
Vaccination of h-Syn tg Mice
For this study, heterozygous tg mice (Line D) expressing hα-syn
under the regulatory control of the platelet-derived growth factor-β
(PDGFβ) promoter (Masliah et al., 2000) were used. These animals
were selected because they display abnormal accumulation of de-
tergent-insoluble hα-syn and develop hα-syn-immunoreactive in-
clusion-like structures in the brain. Although some nuclear staining
has been observed in this model, distinct cytoplasmic inclusion-
like structures have been consistently identified by confocal and
electron microscopy (Masliah et al., 2000; Masliah et al., 2001;
Rockenstein et al., 2002). Furthermore, these animals also display
neurodegenerative and motor deficits that mimic certain aspects
of LBD. Experimental animals were divided into two groups. For
the first group, a total of 20 young (3-month-old) tg mice were im-
munized for 8 months with purified recombinant hα-syn expressed
in E. coli from sequence-verified hα-syn cDNA (n = 10) or CFA alone
(n = 10). For the second group, a total of 20 young adult
(6-month-old) tg mice were immunized for 8 months with recombi-
nant hα-syn (n = 10) or CFA alone (n = 10). The immunization proto-
col consisted first of an injection with recombinant hα-syn (80 g/
ml; 100 l) with CFA (Sigma-Aldrich, St. Louis, MO). Two weeks
later, mice received another injection of hα-syn (80 g/ml; 100 l)
with incomplete Freund’s Adjuvant (FA), followed by reinjection
once a month (for the subsequent 7 months) with hα-syn (80 g/Figure 8. Potential Mechanisms of Antibody-hα-Syn Recognition
and Targeting to the Lysosomal Pathway
(A) Antibodies might recognize hα-syn bound to the membrane.
This complex might in turn be endocytosed and targeted for lyso-
somal degradation. (B) Receptor-mediated endocytosis of the anti-
bodies and hα-syn aggregates that in turn could be targeted for
lysosomal degradation.ml; 100 l) in phosphate-buffered saline. Recombinant hα-syn was
prepared and purified and tested for endotoxins at Elan followinga modified version of a previously described protocol (Hashimoto
et al., 1998).
Determination of Antibody Titers and Relative Affinity to h-Syn
Antibody levels in plasma were determined using 96-well microtiter
plates coated with 0.4 g per well of purified full-length hα-syn.
Samples were incubated overnight followed by goat anti-mouse
IgG alkaline phosphatase-conjugated antibody (1:7500, Promega,
Madison, WI). The plate was read at wavelengths of 450 nm and
550 nm. Results were plotted on a semi-log graph with relative
fluorescence units versus serum dilution. Antibody titer was de-
fined as the dilution at which there was a 50% reduction from the
maximal antibody binding.
To determine the relative affinity of the antibodies for hα-syn,
three assays were performed. In the first, brain homogenates from
nonimmunized hα-syn tg mice were run in a minigel, multichannel
apparatus (Invitrogen, Carlsbad, CA) and transferred to nitrocellu-
lose membranes. Each channel on the membrane was separated
and incubated individually with diluted serum from each of the vac-
cinated mice. Serum dilution was adjusted to 1:1000 for all samples
based on serum titers. Purified recombinant hα-syn was used as a
standard, and all channels were normalized to this as a control.
Channels were then incubated with secondary rabbit anti-mouse
antibody (Vector Laboratories, Burlingame, CA) followed by I125-
tagged protein A (ICN Pharmaceuticals, Costa Mesa, CA) (Alford et
al., 1994). Blots were imaged and analyzed with the PhosphorIm-
ager (Molecular Dynamics, Piscataway, NJ). For the second, to de-
termine the specificity of the antibodies, brain homogenates from
nontg animals, CFA-treated hα-syn tg mice, and immunized hα-syn
tg mice were analyzed by WB with serum from CFA-treated mice
and high relative affinity serum from hα-syn vaccinated tg mice.
Blots were imaged and analyzed on a VersaDoc XL imaging appa-
ratus (BioRad, Hercules, CA). For the third, serial vibratome sec-
tions from an untreated hα-syn tg mouse were incubated in diluted
serum from each of the treated mice (adjusted to 1:1000) followed
by biotinylated horse anti-mouse IgG (1:100, Vector), Avidin
D-horseradish peroxidase (HRP, 1:200, ABC Elite, Vector), and re-
acted with diaminobenzidine tetrahydrochloride (DAB) containing
0.001% H2O2. After microscopic examination, sections were
scored according to the cellular compartment labeled (neuronal
cell bodies, synapses, and inclusions) and the degree of IR (0 =
none; 1 = very mild, 2 = mild, 3 = moderate, 4 = intense).
Epitope Mapping of h-Syn Antibodies
The epitopes recognized by hα-syn antibodies were determined by
an ELISA that measures the binding of an antibody to overlapping
linear peptides that covered the entire hα-syn sequence. C-ter-
minally biotinylated peptides with sequences of hα-syn (Mimo-
topes, San Diego, CA) were prepared as 15 aa long peptides with
an overlap of 12 residues and a step of 3 residues per peptide.
To run the assay, these biotinylated peptides were coated down
overnight at 5 nM onto ELISA plates precoated with streptavidin
(Pierce, Rockford, IL), followed by washing and incubation for 1 hr
with diluted serum samples. Serum samples with titers lower than
5000 were diluted 1:1000 for this incubation. After another washing
step, the bound antibodies were detected using species-specific
secondary antibodies conjugated to HRP in a colorimetric ELISA
format.
Tissue Processing
Following NIH guidelines for the humane treatment of animals,
mice were anesthetized with chloral hydrate and flush-perfused
transcardially with 0.9% saline. Briefly, the right hemibrain was fro-
zen and homogenized for determinations of hα-syn IR by WB (Mas-
liah et al., 2000). The left hemibrain was fixed in 4% paraformalde-
hyde (PFA) and serially sectioned with the vibratome (Leica,
Wetzlar, Germany) for ICC analysis.
Synaptosomal Preparation, Membrane and Cytosolic
Fractionation, and Immunoblot Analysis
Synaptosomal fractions were prepared essentially as previously
described (Dodd et al., 1981a; Dodd et al., 1981b). After resuspen-
sion in 0.32 M sucrose, synaptosomal fractions were analyzed by
SDS-PAGE on a 10% tris-acetate polyacrylamide gel (NuPAGE, In-
Neuron
866vitrogen) and transferred onto Immobilon membranes (Millipore). 2
1For further analysis, total brain homogenates were separated into
membrane and cytosolic fractions, prepared essentially as pre-
viously described (Hashimoto et al., 2002). The cytosolic and mem- D
brane fractions were analyzed by SDS-PAGE on 4%–12% Bis-Tris o
gels and transferred onto Immobilon membranes (Millipore). T
Immunoblots with synaptosomal, cytosolic, and membrane frac- i
tions were probed with an affinity-purified rabbit polyclonal anti- j
body against hα-syn (72-10, 1:5000) (Masliah et al., 2000) or with t
primary antibodies against synaptophysin (1:500, Chemicon, Te- o
mecula, CA) or actin (1:1000, Chemicon), followed by secondary 9
goat anti-rabbit or anti-mouse IgG tagged with HRP (1:5000, Santa- a
Cruz Biotechnology, Inc., Santa Cruz, CA). Blots were visualized by M
ECL and analyzed with a VersaDoc XL imaging apparatus (BioRad). j
T
t
Neuropathological and Immunocytochemical Analysis h
Briefly, as previously described (Masliah et al., 2000), serially sec- s
tioned, free-floating, blind-coded vibratome sections were incu- a
bated overnight at 4°C with an anti-hα-syn-specific antibody (72-

10, 1:500). To analyze the effects of the immunization in glial cell o
activation, sections were labeled with a mouse monoclonal anti-

body against the astroglial marker GFAP (1:500, Chemicon) or a t
rabbit polyclonal antibody against the microglial marker Iba-1 0
(1:1000, Wako Chemicals, Richmond, VA). Incubation with the pri- S
mary antibodies was followed by biotinylated goat anti-rabbit IgG d
or horse anti-mouse IgG (1:100, Vector), Avidin D-HRP (1:200, ABC a
Elite, Vector), and reaction with DAB tetrahydrochloride containing d
0.001% H2O2. Sections were analyzed with the Quantimet 570C V
(Leica) in order to determine the number of hα-syn-immunoreactive b
inclusions, astroglia, or microglia in the temporal cortex, a brain
region often affected in patients with LBD (Hansen et al., 1990). S
For each case, three sections were analyzed, and the results were
A
averaged and expressed as numbers per square millimeter.
c
Double-immunocytochemical analysis was performed as pre-
t
viously described (Hashimoto et al., 2004; Hashimoto et al., 2001)
f
to determine the effects of vaccination on nerve terminal density
r
and hα-syn accumulation in synapses. Vibratome sections were
double-labeled with rabbit polyclonal antibodies against hα-syn
(72-10, 1:5000) detected with Tyramide Red (1:2000, Roche, Swit- Szerland) and with the mouse monoclonal antibody against synapto-
physin (1:15, Chemicon), detected with a horse anti-mouse IgG T
cFITC-tagged secondary antibody (1:75, Vector). For each case,
6sections were immunolabeled in duplicate and analyzed by LSCM
and NIH Image 1.43 software to calculate the percent area of the
Aneuropil covered by synaptophysin-immunoreactive terminals in
the temporal cortex (Mucke et al., 2000) and the proportion of syn-
Taptophysin-immunoreactive terminals that were hα-syn positive
A(Hashimoto et al., 2004).
wControl experiments were performed where sections were immu-
cnolabeled with an antibody against mα-syn (Masliah et al., 2000),
detected with Tyramide Red (1:2000, Roche), or with a rabbit poly-
clonal antibody against β-syn (1:1000, Chemicon), detected with R
FITC-tagged goat anti-rabbit secondary antibody (1:75, Vector). In R
order to confirm the specificity of the primary antibodies, control A
experiments were performed where sections were incubated over- P
night in the absence of primary antibody (deleted), with the primary
antibody preadsorbed for 48 hr with 20-fold excess of the corre- R
sponding peptide or with preimmune serum. To identify if antibod-
ies generated by the vaccinated mice detected hα-syn in the tg A
animals, sections were double labeled with a horse anti-mouse d
FITC-tagged IgG (1:75, Vector) and a rabbit polyclonal antibody l
against hα-syn (72-10, 1:5000), detected with Tyramide Red 2
(1:2000, Roche). To determine if hα-syn colocalized to lysosomes,
B
sections were double labeled with an antibody against hα-syn (72-
s
10, 1:5000), detected with Tyramide Red (1:2000, Roche), and a
3
rabbit polyclonal antibody against cathepsin D (1:500, Calbiochem,
BSan Diego, CA), detected with goat anti-rabbit FITC-tagged sec-
Gondary antibody (1:75, Vector). All sections were processed simul-
ttaneously under the same conditions, and experiments were per-
tformed twice in order to assess the reproducibility of results.
1Sections were imaged with a Zeiss 63X (N.A. 1.4) objective on an
Axiovert 35 microscope (Zeiss, Germany) with an attached B
LMRC1024 LSCM system (BioRad, Wattford, UK) (Masliah et al.,000). Images were analyzed with the image program NIH Image
.43 to determine levels of mα-syn, β-syn, or cathepsin D IR.
etermination of In Vivo Antibody Recognition
f Intracellular h-Syn
o further validate whether antibodies against hα-syn recognized
ntracellular hα-syn, we generated an FITC-tagged antibody for in-
ection into the brains of nontg and hα-syn tg (Line D) mice. For
his purpose, a monoclonal antibody that recognizes aa 118–126
f hα-syn was generated in mice using recombinant hα-syn (clone
E4, Elan Pharmaceuticals). This antibody was concentrated with
10 kDa cutoff concentrator centrifuge tube (Millipore, Billerica,
A) and linked to the FITC molecule utilizing a FluoroTag FITC con-
ugation kit (Sigma) according to the manufacturer’s instructions.
he FITC-tagged hα-syn antibody or a control nonimmune FITC-
agged IgG was injected into the brains of these nontg (n = 5) and
α-syn tg (n = 5) mice (5-month-old). Briefly, as previously de-
cribed (Marr et al., 2003), mice were placed under anesthesia on
Koft stereotaxic apparatus, and each mouse was injected with 3
l of FITC-tagged anti-hα-syn antibody (approximately 0.5 g/l)
r anti-mouse FITC-tagged IgG into the temporal cortex (using a 5
l Hamilton syringe, 0.25 l/min). After 3 days, mice were anesthe-
ized with chloral hydrate and flush-perfused transcardially with
.9% saline. Brains were fixed in 4% PFA for 48 hr and vibratomed.
ections from the brains of these mice were then analyzed by
irect fluorescence or were coimmunolabeled with antibodies
gainst hα-syn (72-10, 1:1000) or cathepsin D (1:500, Calbiochem),
etected with secondary anti-rabbit Texas Red-tagged IgG (1:75,
ector). All sections were imaged with the LSCM as described
efore.
tatistical Analysis
fter all results were obtained, the code was broken and statistical
omparisons between groups were performed utilizing the two-
ailed unpaired Student’s t test. Linear regression analysis was per-
ormed to ascertain the relationship among variables. The Bonfer-
oni correction was applied to account for multiple comparisons.
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